A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression-Reference-Cited by-同舟云学术

A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression

Published:2000-12 Issue:1-2 Volume:61 Page:119-126
ISSN:0165-0327
Container-title:Journal of Affective Disorders
language:en
Short-container-title:Journal of Affective Disorders

Author:

Feighner J.P,Ehrensing R.H,Kastin A.J,Leonard B.E,Sverdlov L,Nicolau G,Patel A,Hlavka J,Abajian H,Noble J.F

Publisher

Elsevier BV

Subject

Psychiatry and Mental health,Clinical Psychology

Reference18 articles.

1. Dose-related biphasic effect of prolyl-leucyl-glycinamide (MIF-1) in depression;Ehrensing;Am. J. Psychiatry,1978

2. Improvement in major depression after low subcutaneous doses of MIF-1;Ehrensing;J. Affect. Disord.,1994

3. Efficacy issues with antidepressants;Fawcett;J. Clin. Psychol.,1997

4. Enkephalin and other peptides reduce passiveness;Kastin;Pharmacol. Biochem. Behav.,1978

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Behavioral effects of neuropeptides in rodent models of depression and anxiety;Peptides;2010-04

2. Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients;International Clinical Psychopharmacology;2008-01

3. From MIF-1 to endomorphin: The Tyr-MIF-1 family of peptides;Peptides;2007-12

4. Cognitive Dysfunction and Depression May Decrease Activities in Daily Life More Strongly Than Pain in Community-Dwelling Elderly Adults Living With Persistent Pain;Pain Practice;2007-09

5. Developing selectively nonselective drugs for treating CNS disorders;Drug Discovery Today: Therapeutic Strategies;2006-12